Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (1-10 of 268) with videos related to

Pageof 27
Sort By:
The Lancet. Respiratory Medicine|November 10, 2016
Targeted therapy outcomes in RET-rearranged lung cancers: drug or driver?Alexander Drilon
Clinical Advances in Hematology & Oncology : H&O|July 2, 2024
Management of patients with NTRK fusion-positive lung cancerAlexander Drilon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2016
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-LifeAlexander Drilon
Cancer Genetics|March 25, 2022
TRK inhibitor activity and resistance in TRK fusion-positive cancers in adultsGuilherme Harada, Alexander Drilon
Advances in Experimental Medicine and Biology|December 16, 2015
KRAS-Mutant Lung Cancers in the Era of Targeted TherapyJarushka Naidoo, Alexander Drilon
Translational Lung Cancer Research|January 25, 2021
Decade in review: a new era for RET-rearranged lung cancersNoura J Choudhury, Alexander Drilon
Nature|July 17, 2020
An umbrella approach to test lung cancer therapiesAlexander Drilon, Matthew D Hellmann
Nature Reviews. Clinical Oncology|October 19, 2018
NTRK fusion-positive cancers and TRK inhibitor therapyEmiliano Cocco, Maurizio Scaltriti, Alexander Drilon
Cancer Discovery|December 2, 2022
Precision Oncology: 2022 in ReviewEzra Rosen, Alexander Drilon, Debyani Chakravarty
Clinical and Translational Medicine|October 15, 2024
Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancerAntoine Desilets, Matteo Repetto, Alexander Drilon
Pageof 27

Showing results (1-10 of 268) with videos related to

Sort By:
Pageof 27
The Lancet. Respiratory Medicine|November 10, 2016
Targeted therapy outcomes in RET-rearranged lung cancers: drug or driver?Alexander Drilon
Clinical Advances in Hematology & Oncology : H&O|July 2, 2024
Management of patients with NTRK fusion-positive lung cancerAlexander Drilon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2016
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-LifeAlexander Drilon
Cancer Genetics|March 25, 2022
TRK inhibitor activity and resistance in TRK fusion-positive cancers in adultsGuilherme Harada, Alexander Drilon
Advances in Experimental Medicine and Biology|December 16, 2015
KRAS-Mutant Lung Cancers in the Era of Targeted TherapyJarushka Naidoo, Alexander Drilon
Translational Lung Cancer Research|January 25, 2021
Decade in review: a new era for RET-rearranged lung cancersNoura J Choudhury, Alexander Drilon
Nature|July 17, 2020
An umbrella approach to test lung cancer therapiesAlexander Drilon, Matthew D Hellmann
Nature Reviews. Clinical Oncology|October 19, 2018
NTRK fusion-positive cancers and TRK inhibitor therapyEmiliano Cocco, Maurizio Scaltriti, Alexander Drilon
Cancer Discovery|December 2, 2022
Precision Oncology: 2022 in ReviewEzra Rosen, Alexander Drilon, Debyani Chakravarty
Clinical and Translational Medicine|October 15, 2024
Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancerAntoine Desilets, Matteo Repetto, Alexander Drilon
Pageof 27